Junbin Han1, Hui Liu, Chunling Liu, Hongjun Jin, Joel S Perlmutter, Terrance M Egan, Zhude Tu. 1. Departments of aRadiology bNeurology, Neuroscience, Physical Therapy and Occupational Therapy, Washington University School of Medicine cDepartment of Pharmacological and Physiological Science, Saint Louis University School of Medicine, St. Louis, Missouri, USA.
Abstract
OBJECTIVE: The P2X7 receptor (P2X7R) is a key regulatory element in the neuroinflammatory cascade that provides a promising target for imaging neuroinflammation. GSK1482160, a P2X7R modulator with nanomolar binding affinity and high selectivity, has been successfully radiolabeled and utilized for imaging P2X7 levels in a mouse model of lipopolysaccharide-induced systemic inflammation. In the current study, we further characterized its binding profile and determined whether [C]GSK1482160 can detect changes in P2X7R expression in a rodent model of multiple sclerosis. METHODS: [C]GSK1482160 was synthesized with high specific activity and high radiochemical purity. Radioligand saturation and competition binding assays were performed for [C]GSK1482160 using HEK293-hP2X7R living cells. Micro-PET studies were carried out in nonhuman primates. In vitro autoradiography and immunohistochemistry studies were then carried out to evaluate tracer uptake and P2X7 expression in experimental autoimmune encephalomyelitis (EAE) rat lumbar spinal cord at EAE-peak and EAE-remitting stages compared with sham rats. RESULTS: [C]GSK1482160 binds to HEK293-hP2X7R living cells with high binding affinity (Kd=5.09±0.98 nmol/l, Ki=2.63±0.6 nmol/l). Micro-PET studies showed high tracer retention and a homogeneous distribution in the brain of nonhuman primates. In the EAE rat model, tracer uptake of [C]GSK1482160 in rat lumbar spinal cord was the highest at the EAE-peak stage (277.74±79.74 PSL/mm), followed by the EAE-remitting stage(149.00±54.14 PSL/mm) and sham (66.37±1.48 PSL/mm). The tracer uptake correlated strongly with P2X7-positive cell counts, activated microglia numbers, and disease severity. CONCLUSION: We conclude that [C]GSK1482160 has the potential for application in monitoring neuroinflammation.
OBJECTIVE: The P2X7 receptor (P2X7R) is a key regulatory element in the neuroinflammatory cascade that provides a promising target for imaging neuroinflammation. GSK1482160, a P2X7R modulator with nanomolar binding affinity and high selectivity, has been successfully radiolabeled and utilized for imaging P2X7 levels in a mouse model of lipopolysaccharide-induced systemic inflammation. In the current study, we further characterized its binding profile and determined whether [C]GSK1482160 can detect changes in P2X7R expression in a rodent model of multiple sclerosis. METHODS: [C]GSK1482160 was synthesized with high specific activity and high radiochemical purity. Radioligand saturation and competition binding assays were performed for [C]GSK1482160 using HEK293-hP2X7R living cells. Micro-PET studies were carried out in nonhuman primates. In vitro autoradiography and immunohistochemistry studies were then carried out to evaluate tracer uptake and P2X7 expression in experimental autoimmune encephalomyelitis (EAE) rat lumbar spinal cord at EAE-peak and EAE-remitting stages compared with sham rats. RESULTS: [C]GSK1482160 binds to HEK293-hP2X7R living cells with high binding affinity (Kd=5.09±0.98 nmol/l, Ki=2.63±0.6 nmol/l). Micro-PET studies showed high tracer retention and a homogeneous distribution in the brain of nonhuman primates. In the EAE rat model, tracer uptake of [C]GSK1482160 in rat lumbar spinal cord was the highest at the EAE-peak stage (277.74±79.74 PSL/mm), followed by the EAE-remitting stage(149.00±54.14 PSL/mm) and sham (66.37±1.48 PSL/mm). The tracer uptake correlated strongly with P2X7-positive cell counts, activated microglia numbers, and disease severity. CONCLUSION: We conclude that [C]GSK1482160 has the potential for application in monitoring neuroinflammation.
Authors: Lav K Parvathenani; Svetlana Tertyshnikova; Corinne R Greco; Susan B Roberts; Barbara Robertson; Rand Posmantur Journal: J Biol Chem Date: 2003-01-27 Impact factor: 5.157
Authors: Paul R Territo; Jill A Meyer; Jonathan S Peters; Amanda A Riley; Brian P McCarthy; Mingzhang Gao; Min Wang; Mark A Green; Qi-Huang Zheng; Gary D Hutchins Journal: J Nucl Med Date: 2016-10-20 Impact factor: 10.057
Authors: Davide Ferrari; Cinzia Pizzirani; Elena Adinolfi; Roberto M Lemoli; Antonio Curti; Marco Idzko; Elisabeth Panther; Francesco Di Virgilio Journal: J Immunol Date: 2006-04-01 Impact factor: 5.422
Authors: Marloes Prins; Charlotta Eriksson; Anne Wierinckx; John G J M Bol; Rob Binnekade; Fred J H Tilders; Anne-Marie Van Dam Journal: PLoS One Date: 2013-12-23 Impact factor: 3.240
Authors: Wolfgang Fischer; Heike Franke; Ute Krügel; Heiko Müller; Klaus Dinkel; Brian Lord; Michael A Letavic; David C Henshall; Tobias Engel Journal: PLoS One Date: 2016-06-09 Impact factor: 3.240
Authors: Jeffrey H Meyer; Simon Cervenka; Min-Jeong Kim; William C Kreisl; Ioline D Henter; Robert B Innis Journal: Lancet Psychiatry Date: 2020-10-21 Impact factor: 27.083
Authors: Donatienne Van Weehaeghe; Michel Koole; Mark E Schmidt; Stephanie Deman; Andreas H Jacobs; Erika Souche; Kim Serdons; Stefan Sunaert; Guy Bormans; Wim Vandenberghe; Koen Van Laere Journal: Eur J Nucl Med Mol Imaging Date: 2019-06-26 Impact factor: 9.236
Authors: Bieneke Janssen; Danielle J Vugts; Shane M Wilkinson; Dieter Ory; Sylvie Chalon; Jeroen J M Hoozemans; Robert C Schuit; Wissam Beaino; Esther J M Kooijman; Johan van den Hoek; Mansoor Chishty; Aurélie Doméné; Anke Van der Perren; Alessandro Villa; Adriana Maggi; Ger T Molenaar; Uta Funke; Rostislav V Shevchenko; Veerle Baekelandt; Guy Bormans; Adriaan A Lammertsma; Michael Kassiou; Albert D Windhorst Journal: Sci Rep Date: 2018-04-26 Impact factor: 4.379